This week we highlight patent infringement claims, ongoing manufacturing expansion, underrepresentation of pregnant women in clinical data, and the National Institutes of Health’s All of Us genomic study. Each week we highlight five things you need to know about in the life sciences industry. Here’s the ... READ MORE >
Life sciences
5 things to know in life sciences: Week of March 7, 2022
This week we highlight changes in drug exclusivity, international mRNA manufacturing expansion, clinical trial challenges in Russia, and recent Food and Drug Administration activities. Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest. Top 10 ... READ MORE >
5 things to know in life sciences: Week of Feb. 28, 2022
This week we highlight clinical holds on cell and gene therapies, clinical trials and patient experience, artificial intelligence and identifying bone fractures, and more. Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest. Cell and gene therapies ... READ MORE >
5 things to know in life sciences: Week of Feb. 21, 2022
This week we highlight a personalized blood testing company, an artificial intelligence-based software platform capable of detecting heart disease and a promising mRNA technology that can heal bone defects. In addition, we look at a novel company providing a kidney care solution as well as Nintendo and ... READ MORE >
5 things to know in life sciences: Week of Feb. 14, 2022
This week, we highlight Moderna’s contract extension with Rovi, a recent report that indicates the global contract development and manufacturing organization (CDMO) market is expected to grow by over $8.65 billion by 2026, Robert Califf’s return as Food and Drug Administration commissioner, an artificial ... READ MORE >
5 things to know in life sciences: Week of Feb. 7, 2022
This week we highlight regulatory challenges for the United States and China; a softening of guidelines in the prescription of opioids; and record-breaking sales figures for Pfizer as it sees a more than 600% increase in vaccine revenue. Finally, we look at a new cartilage implant inspired by spiders and ... READ MORE >
Clinical trials and life sciences services: Spring 2022 outlook
While there has been a downward trend in COVID-19 clinical trial starts, these trials maintain strong momentum into 2022. Enrollment remains at the top of the list of challenges facing clinical trials. Virtual trial companies have seen exponential growth over the past two quarters. Read about ... READ MORE >
Biopharma business outlook: Spring 2022
Drug approvals in 2021 continued at a pace consistent with prior years, but a large backlog of inspections is slowing some approvals. Cell and gene therapies investment is growing rapidly and promises substantial revenue growth in the coming years. Read about other sectors 2021 FDA approvals ... READ MORE >
The need for regulatory framework modernization: Spring 2022 medtech outlook
Having a well-defined pathway to quickly review and provide clearance for low-risk devices will help alleviate the backlog and shift resources to more critical and high-risk device applications. As the pace of innovation increases and the number of novel devices brought to market continues to grow, ... READ MORE >
Macroeconomic drivers for life sciences: Spring 2022 outlook
The three areas that middle market life sciences companies should pay specific attention to are supply chains, labor and capital markets. We anticipate a decreased appetite from private investors to pay high company valuations, but an uptick in the number of life sciences startups. This presents an ... READ MORE >